nafamostat has been researched along with Vulvar Neoplasms in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Vulvar Neoplasms: Tumors or cancer of the VULVA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamashita, Y | 1 |
| Ishiguro, Y | 1 |
| Sano, D | 1 |
| Kimura, M | 1 |
| Fujita, K | 1 |
| Yoshida, T | 1 |
| Horiuchi, C | 1 |
| Taguchi, T | 1 |
| Matsuda, H | 1 |
| Mikami, Y | 1 |
| Tsukuda, M | 1 |
1 other study available for nafamostat and Vulvar Neoplasms
| Article | Year |
|---|---|
Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Benzamidines; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell | 2007 |